Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 09 06 2023
accepted: 20 07 2023
medline: 22 8 2023
pubmed: 21 8 2023
entrez: 21 8 2023
Statut: epublish

Résumé

Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic calicheamicin payload

Identifiants

pubmed: 37600823
doi: 10.3389/fimmu.2023.1237738
pmc: PMC10435844
doi:

Substances chimiques

Inotuzumab Ozogamicin P93RUU11P7
Antibodies, Monoclonal, Humanized 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1237738

Informations de copyright

Copyright © 2023 Rubinstein and O’Brien.

Déclaration de conflit d'intérêts

MO’B previously received research support from Pfizer Inc. through a Pfizer ASPIRE Hematology/Oncology Grant which is completed. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Med. 2021 Oct;27(10):1797-1805
pubmed: 34642489
Leukemia. 2022 Jun;36(6):1516-1524
pubmed: 35468945
Hepatology. 2019 Feb;69(2):831-844
pubmed: 30120894
J Clin Oncol. 2022 Mar 20;40(9):932-944
pubmed: 34767461
Front Immunol. 2020 Apr 03;11:489
pubmed: 32318059
Lancet Haematol. 2017 Aug;4(8):e387-e398
pubmed: 28687420
Blood. 2022 Aug 4;140(5):451-463
pubmed: 35605184
Blood. 2021 Mar 25;137(12):1582-1590
pubmed: 33067614
Blood. 2014 Jan 2;123(1):70-7
pubmed: 24222333
Am J Hematol. 2019 Apr;94(4):408-416
pubmed: 30623490
Leuk Res. 2007 May;31(5):599-604
pubmed: 16959316
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cytometry B Clin Cytom. 2011 Mar;80(2):83-90
pubmed: 20872890
Cancer. 2013 Aug 1;119(15):2728-36
pubmed: 23633004
Blood. 2018 Aug 23;132(8):815-824
pubmed: 29997224
Bone Marrow Transplant. 2018 Apr;53(4):449-456
pubmed: 29330398
J Clin Oncol. 2022 Mar 20;40(9):956-967
pubmed: 35007127
Blood Adv. 2023 Jan 24;7(2):251-255
pubmed: 35500285
Lancet Haematol. 2023 May;10(5):e333-e345
pubmed: 37001534
Biol Blood Marrow Transplant. 2016 Jul;22(7):1306-1312
pubmed: 27108694
Cancers (Basel). 2023 Mar 19;15(6):
pubmed: 36980732
Lancet Oncol. 2018 Feb;19(2):240-248
pubmed: 29352703
Cancer. 2022 Feb 01;128(3):529-535
pubmed: 34633671
Biol Blood Marrow Transplant. 2013 Mar;19(3):500-3
pubmed: 23211838
Blood. 2010 Apr 8;115(14):2740-8
pubmed: 20124218
Blood Adv. 2017 Jun 27;1(15):1167-1180
pubmed: 29296758
Blood Cancer Discov. 2022 Mar 01;3(2):103-115
pubmed: 35015683
Leuk Res. 2020 Jan;88:106283
pubmed: 31790983
Leukemia. 2022 Mar;36(3):648-655
pubmed: 34725453
Cancer. 2018 Mar 15;124(6):1150-1159
pubmed: 29266189
J Clin Oncol. 2020 Feb 20;38(6):602-612
pubmed: 31825704
J Clin Oncol. 2022 Mar 20;40(9):945-955
pubmed: 34882493
Am J Hematol. 2021 Aug 1;96(8):1000-1007
pubmed: 33991360
AAPS J. 2016 Sep;18(5):1101-1116
pubmed: 27198897
J Oncol Pharm Pract. 2023 Jun;29(4):840-845
pubmed: 35293248
Cancer Res. 2008 Aug 1;68(15):6300-5
pubmed: 18676854
Biol Blood Marrow Transplant. 2020 Nov;26(11):e280-e285
pubmed: 32755637
J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):211-222
pubmed: 30859374
Int J Mol Sci. 2021 Jun 16;22(12):
pubmed: 34208575
Clin Cancer Res. 2017 Apr 1;23(7):1760-1770
pubmed: 27683177
Pediatr Blood Cancer. 2021 Aug;68(8):e29067
pubmed: 33871892
Br J Haematol. 2021 Jun;193(6):1172-1177
pubmed: 33529389
Pediatr Blood Cancer. 2015 Jun;62(6):964-9
pubmed: 25728039
Blood. 2023 Mar 23;141(12):1379-1388
pubmed: 36548957
J Clin Oncol. 2023 May 31;:JCO2202200
pubmed: 37257143
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Lancet Oncol. 2012 Sep;13(9):936-45
pubmed: 22898679
JAMA. 2021 Mar 2;325(9):833-842
pubmed: 33651090
Blood. 2021 May 13;137(19):2657-2661
pubmed: 33512436
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Blood. 2020 Oct 15;136(16):1803-1812
pubmed: 32589723
Clin Transl Sci. 2021 Jan;14(1):184-193
pubmed: 32812370
Leukemia. 2007 Nov;21(11):2240-5
pubmed: 17657218
Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729
pubmed: 31039409
Lancet Haematol. 2023 Jun;10(6):e433-e444
pubmed: 37187201
Pediatr Blood Cancer. 2014 Feb;61(2):369-72
pubmed: 24000241
Cancers (Basel). 2020 Jan 28;12(2):
pubmed: 32012891
Leukemia. 2019 Apr;33(4):884-892
pubmed: 30267011
Cancer. 2023 May 1;129(9):1384-1393
pubmed: 36829303
Am J Hematol. 2015 Mar;90(3):193-6
pubmed: 25407953
Blood. 2006 Nov 15;108(10):3302-4
pubmed: 16896151
Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):296-301
pubmed: 23313065
J Immunol. 1995 May 1;154(9):4466-75
pubmed: 7722303
J Clin Oncol. 2020 Aug 10;38(23):2628-2638
pubmed: 32496902
Nat Med. 2021 May;27(5):842-850
pubmed: 33888899
Blood. 2003 Sep 1;102(5):1578-82
pubmed: 12738663
Lancet Haematol. 2020 Jan;7(1):e61-e72
pubmed: 31818728
Immunol Rev. 2009 Jul;230(1):128-43
pubmed: 19594633
Leukemia. 2022 May;36(5):1215-1226
pubmed: 35368047
Cancer. 2018 Oct 15;124(20):4044-4055
pubmed: 30307611
Blood Adv. 2022 Jan 25;6(2):600-610
pubmed: 34794180
Leukemia. 2023 Jan;37(1):53-60
pubmed: 36310183
Haematologica. 2022 Sep 01;107(9):2064-2071
pubmed: 35142153
Br J Haematol. 2020 Sep;190(6):822-836
pubmed: 32133623
J Clin Oncol. 2020 Jun 10;38(17):1938-1950
pubmed: 32286905
N Engl J Med. 2016 Sep 15;375(11):1044-53
pubmed: 27626518
Br J Haematol. 2020 Oct;191(1):123-126
pubmed: 32648276
Front Oncol. 2022 Jun 15;12:933317
pubmed: 35785209
Lancet Oncol. 2012 Apr;13(4):403-11
pubmed: 22357140
Leukemia. 2012 Feb;26(2):255-64
pubmed: 21869836
Clin Cancer Res. 2021 May 15;27(10):2742-2754
pubmed: 33602684
J Clin Oncol. 2010 Apr 20;28(12):2085-93
pubmed: 20308665
Cancer. 2019 Jul 15;125(14):2474-2487
pubmed: 30920645
J Clin Invest. 2019 Mar 12;129(5):2123-2132
pubmed: 30860496
Cancer. 2021 Apr 1;127(7):1039-1048
pubmed: 33259056
Blood. 2004 Mar 1;103(5):1807-14
pubmed: 14615373
Cancer. 2021 Mar 15;127(6):905-913
pubmed: 33231879
JAMA Oncol. 2018 Feb 01;4(2):230-234
pubmed: 28859185
Blood Adv. 2022 Apr 12;6(7):2167-2182
pubmed: 34920453
Hematol Oncol. 2022 Oct;40(4):734-742
pubmed: 35618655
Leuk Lymphoma. 2020 Aug;61(8):2012-2015
pubmed: 32378440

Auteurs

Jeremy D Rubinstein (JD)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Maureen M O'Brien (MM)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH